Imagine a world where we could drastically reduce the risk of one of the deadliest cancers for women. That world is becoming a reality, thanks to a groundbreaking surgical technique that slashes the risk of ovarian cancer by a staggering 80%. But here's where it gets even more fascinating: this life-saving approach doesn't involve complex, experimental treatments—it's a simple addition to surgeries many women already undergo.
A recent study published in JAMA Network Open (https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.57267?guestAccessKey=b761765e-d009-4b90-bee6-e0c930b248c1) reveals that opportunistic salpingectomy (OS)—the removal of fallopian tubes during routine gynecological procedures like hysterectomies or tubal ligation—can dramatically lower the risk of the most lethal form of ovarian cancer. This innovation, pioneered by researchers at the University of British Columbia (UBC), BC Cancer, and Vancouver Coastal Health, challenges the long-held belief that ovarian cancer originates in the ovaries. Instead, evidence shows that most cases begin in the fallopian tubes.
But here's where it gets controversial: Should this procedure become the standard of care for all eligible women, or are there ethical concerns about removing healthy tissue during routine surgeries? Let’s dive deeper.
The Canadian province of British Columbia (B.C.) led the charge, becoming the first jurisdiction globally to offer OS in 2010. Since then, the approach has gained momentum, with approximately 80% of hysterectomies and tubal ligations in B.C. now including fallopian tube removal. Globally, 24 countries have adopted OS as a preventive measure, backed by organizations like the Society of Obstetrics and Gynaecology of Canada.
The study, led by the Ovarian Cancer Observatory, analyzed health data from over 85,000 individuals who underwent gynecological surgeries in B.C. between 2008 and 2020. The results were striking: those who had OS were 78% less likely to develop serous ovarian cancer, the most common and deadly subtype. Even in the rare cases where cancer occurred post-OS, the tumors were less aggressive. These findings were further validated by global pathology data, cementing OS as a game-changer.
And this is the part most people miss: OS doesn’t just prevent cancer—it does so without significant side effects. By leaving the ovaries intact, hormone production remains unaffected, minimizing the impact on women’s health. Dr. Gillian Hanley, co-senior author of the study, emphasizes, ‘This relatively simple change in surgical practice can have a profound and life-saving impact.’
Ovarian cancer is notoriously deadly, with approximately 3,100 Canadians diagnosed annually and 2,000 succumbing to the disease. The lack of reliable screening tests means most cases are diagnosed at advanced stages, when treatment options are limited. OS offers a proactive solution, addressing the root cause before it becomes a problem. As Dr. Dianne Miller, who coined the term OS, aptly puts it, ‘If there’s one thing better than curing cancer, it’s never getting it in the first place.’
The global impact of OS is undeniable. Researchers estimate that widespread adoption could prevent thousands of ovarian cancer cases yearly. B.C. has already expanded OS to include routine surgeries performed by general and urologic surgeons, setting a precedent for other regions. Dr. David Huntsman, another co-senior author, urges clinicians to embrace this approach, stating, ‘Not offering this surgical add-on may leave patients unnecessarily vulnerable.’
But here’s the question we must ask: As OS gains traction, how do we ensure equitable access to this life-saving procedure worldwide? And what role should patient education play in this conversation? Share your thoughts in the comments—let’s spark a dialogue that could shape the future of ovarian cancer prevention.
